Search
  • Search


Ireland: Tenders/Mater Misericordiae University Hospital Ltd/The supply of Radiopharmaceuticals for use in Petct including Fludeoxyglucose F18 and PSMA.
  1. Supplier selection

    Dec 1, 2025 12:00 AMDecember 1, 2025 12:00 AM
  2. Result notice published

    Dec 5, 2025 2:46 PMDecember 5, 2025 2:46 PM

Brief

The supply of Radiopharmaceuticals for use in Petct including Fludeoxyglucose F18 and PSMA.

Published deadline passed

The published deadline has passed. For multi-stage competitions a later tender deadline may still apply — check the notice or portal for the current phase.

Qualification deadline
Dec 4, 2025Expired
Procedure
Without prior noticeTwo stages
Agreement
Buying goods

Brief

Mater Misericordiae University Hospital Ltd intends to enter into an agreement with Curium Pharma Ireland Limited for the supply of Fludeoxyglucose F18 and prostate-specific membrane antigen (PSMA) radiotracers for use in PET/CT scans in Dublin. The contract will have a duration of 4 years and an estimated total value of 3,000,000 €. This direct award is due to Curium Pharma Ireland Limited being the sole licensed provider of these radiopharmaceuticals in Ireland, ensuring continuity of service and value for money.

Farmasøytisk engroshandel

Result

TED
  • Number of tenders received
    0
  • Contract value
    €3,000,000

Custom Assessment Criteria

  • Get answers to your bid/no-bid criteria

    Set them up once and Cobrief answers them in every tender

Will you bid?

The agent sets up the bid and writes the first draft. Free for 14 days.

Previous winners

  • Who are you up against?

    The suppliers who have won similar contracts at Mater Misericordiae University Hospital Ltd

From the notice

  • This is a VEAT notice to indicate that the Mater Misericordiae University Hospital (MMUH) intends to utilize EU public procurement directive Art 32.2(b) (iii) negotiated procedure without prior publication in the following case. (B) Where works, supplies or services can be supplied only by a particular economic operator for any of the following reasons: (iii) competition is absent for technical reasons. This notice is to indicate that the Mater Misericordiae University Hospital (MMUH) intends to contract with Curium Pharma Ireland Limited for a 4 year period for the continued provision of the Fludeoxyglucose F18 (FDG) and prostate-specific membrane antigen (PSMA) radiotracers which are employed within the PET/CT facility to facilitate the accurate diagnosis of malignant diseases. These products are essential for the operation of the hospital’s PET/CT facility and are required to enable accurate diagnosis and monitoring of cancers. The justification for this decision is that Curium is the sole licensed provider of these radiopharmaceuticals within the jurisdiction. No other economic operator holds the necessary authorisations or regulatory approvals to manufacture, distribute, and supply these products for clinical use in Ireland. MMUH is aware that an alternative provider may enter the market in 13-18 months. The hospital is entering into a 4 year contract on the basis of : Economic Efficiency: A four-year contract offers significantly lower total cost compared to shorter-term alternatives, even when factoring in the potential entry of a new supplier in 13-18 months. Market Uncertainty: While a new supplier is expected to enter the market in approximately two years, there is no guarantee regarding their operational readiness, regulatory approvals, or ability to meet the hospital’s supply requirements at that time. Continuity of Supply: The selected provider has demonstrated proven capability and reliability in delivering the required product. A four-year term ensures uninterrupted service and mitigates risks associated with supplier transition or market instability. Conclusion: The contracting authority considers that no reasonable alternative or substitute exists at present and that competition is absent for technical and economic reasons. The direct award is necessary to ensure continuity of service and value for money.

  • Contact

    spriest@mater.ie
  • Type
    Result · Prequalification
  • Location
    Dublin
  • Main code
    Pharmaceutical products
    33600000

Similar active competitions

  • Inštitút nukleárnej a molekulárnej medicíny

    Persontransporttjenester

    Spotrebný materiál pre prípravu 68Ga a 177Lu označených rádiofarmák

    Inštitút nukleárnej a molekulárnej medicíny potrebuje pravidelné dodávky spotrebného materiálu na prípravu rádiofarmák označených ⁶⁸Ga a ¹⁷⁷Lu počas 1 roka, v rámci rámcovej dohody s maximálnou celkovou hodnotou 288 734,10 EUR. Materiál musí byť kompatibilný so zariadením Modular-Lab eazy od spoločnosti Eckert & Ziegler Radiopharma a dodávať sa na určené miesto v Košickom kraji. Ponuky sa hodnotia podľa jednotkovej ceny za kus; kritériá sú uvedené s váhou 50 bodov každé. Predchádzajúcu zákazku rovnakého názvu získala spoločnosť MGP, spol. s r.o.

    Framework agreement
    Nov 27, 2026(8 days)
    €288,734
  • Fakultní nemocnice Hradec Králové

    Radiofarmaka 177Lu-PSMA

    Fakultní nemocnice Hradec Králové potřebuje průběžné dodávky radiofarmaka 177Lu-PSMA (vipivotid tetraxetan) pro léčbu pacientů s karcinomem prostaty, a to po dobu 4 let podle aktuálních potřeb nemocnice. Předmětem je injekční roztok pro intravenózní podání včetně dopravy na pracoviště zadavatele v Královéhradeckém kraji; maximální celková hodnota zakázky činí 59 345 304 Kč. Nabídky budou hodnoceny výhradně podle celkové ceny bez DPH za jednu dávku (100 %).

    Competition
    Dec 15, 2026(26 days)
    CZK 59,345,304
  • Fakultní nemocnice Motol a Homolka

    Medisinsk engroshandel

    Dodávky radiofarmaka JOFLUPAN

    Fakultní nemocnice Motol a Homolka potřebuje dodávky radiofarmaka JOFLUPAN pro Kliniku nukleární medicíny a endokrinologie FNMH po dobu 4 let, s maximální celkovou hodnotou 6 438 000 Kč. Dodávky se budou realizovat v Hlavním městě Praze. Nabídky budou hodnoceny pouze na základě ceny (100 %).

    Competition
    Nov 19, 2026(0 days)
    CZK 6,438,000